HomeDBV • FRA
add
DBV Technologies SA
Nakaraang pagsara
€2.08
Sakop ng araw
€1.89 - €1.91
Sakop ng taon
€0.44 - €2.00
Market cap
247.87M EUR
Average na Volume
291.00
P/E ratio
-
Dividend yield
-
Primary exchange
EPA
Mga balita tungkol sa merkado
Mga Financial
Income Statement
Kita
Net na kita
| (USD) | Mar 2025info | Y/Y na pagbabago |
|---|---|---|
Kita | 753.00K | -46.48% |
Gastos sa pagpapatakbo | 27.37M | -8.66% |
Net na kita | -27.08M | 0.97% |
Net profit margin | -3.60K | -85.03% |
Kita sa bawat share | -0.23 | 91.18% |
EBITDA | -25.67M | 9.96% |
Aktuwal na % ng binabayarang buwis | — | — |
Balance Sheet
Kabuuang asset
Kabuuang sagutin
| (USD) | Mar 2025info | Y/Y na pagbabago |
|---|---|---|
Cash at mga panandaliang investment | 12.96M | -87.23% |
Kabuuang asset | 50.56M | -65.34% |
Kabuuang sagutin | 47.69M | 39.27% |
Kabuuang equity | 2.87M | — |
Natitirang share | 136.72M | — |
Presyo para makapag-book | 69.33 | — |
Return on assets | -114.52% | — |
Return on capital | -299.45% | — |
Cash Flow
Net change in cash
| (USD) | Mar 2025info | Y/Y na pagbabago |
|---|---|---|
Net na kita | -27.08M | 0.97% |
Cash mula sa mga operasyon | -19.67M | 43.31% |
Cash mula sa pag-invest | -375.00K | 82.41% |
Cash mula sa financing | 45.00K | 172.58% |
Net change in cash | -19.49M | 51.07% |
Malayang cash flow | -9.34M | 66.16% |
Tungkol
DBV Technologies SA is a publicly owned French biopharmaceutical firm headquartered in Bagneux, France. DBV Technologies is known for developing "Viaskin" technology for administering allergens or antigens to intact skin while avoiding any transfer to the blood. Viaskin Peanut clinical development has received Fast Track designation from the US Food and Drug Administration. Wikipedia
Itinatag
Mar 29, 2002
Website
Mga Empleyado
106
